Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory

Similar documents
Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014

Genetic Counselling in relation to genetic testing

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

Sharan Goobie, MD, MSc, FRCPC

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016

CHROMOSOMAL MICROARRAY (CGH+SNP)

Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University

Corporate Medical Policy

Approach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD

Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs

Approach to the Genetic Diagnosis of Neurological Disorders

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns

Congenital Heart Disease How much of it is genetic?

Clinical evaluation of microarray data

GENETICS ROTATION OBJECTIVES MATERNAL-FETAL MEDICINE FELLOWSHIP

Evolution of Genetic Testing. Joan Pellegrino MD Associate Professor of Pediatrics SUNY Upstate Medical University

Prenatal Diagnosis: Are There Microarrays in Your Future?

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Genetics update and implications for (General) Practice

Updating penetrance estimates for syndromes with variable phenotypic manifestation. Adele Corrigan June 27th

Epilepsy Genetics Service Kings College Hospital & St Thomas s Hospital, London

review Genetics IN Medicine 13

22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)

Case 1B. 46,XY,-14,+t(14;21)

Benefits and pitfalls of new genetic tests

RACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017

CGH microarray studies in idiopathic developmental/ cognitive impairment: association of historical and clinical features and the De Vries Score

CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

Dr Dipti Deshmukh. Mayu Uemura. 11th September Introduction

Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray

Microarray Comparative Genomic Hybridisation (array CGH)

CANCER GENETICS PROVIDER SURVEY

Committee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler

Medical Policy. MP Invasive Prenatal (Fetal) Diagnostic Testing

Genetics and Genomics: Applications to Developmental Disability

What s the Human Genome Project Got to Do with Developmental Disabilities?

Chromosome Microarray Analysis (CMA)

Genetics: More Than 23 and Me

SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017

MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

CHROMOSOME MICROARRAY TESTING

Human Genetic Variation Copy Number Variation

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Increasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics

What is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD

DiGeorge Syndrome (DGS) Registry Data Collection Form_. Patient Identification: Patient Name (first, middle, last)

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Isolated Choroid Plexus Cyst

Non-Mendelian inheritance

Introduction to Genetics

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

DNA is the genetic material that provides instructions for what our bodies look like and how they function. DNA is packaged into structures called

Genetic Testing for Single-Gene and Multifactorial Conditions

National Medical Policy

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509

Understanding The Genetics of Diamond Blackfan Anemia

THE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY

GENOME-WIDE ASSOCIATION STUDIES

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Why did this happen? Genetic and teratologic considerations in CHD Jennifer Kussmann, MS,CGC. The Children's Mercy Hospital, 2014.

Supplemental Information

Cerebral Malformation gene panel

chromosomal anomalies and mental pdf Chapter 8: Chromosomes and Chromosomal Anomalies (PDF) Chromosomal abnormalities -A review - ResearchGate

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

CHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS)

SNP Microarray. Prenatal

Chromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases

%(6/31) [DOI] /j.issn

Red flags for clinical practice - guidance on indicators that your patient may have a genetic condition

American Psychiatric Nurses Association

Investigating rare diseases with Agilent NGS solutions

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Human Genetics 542 Winter 2018 Syllabus

Seven cases of intellectual disability analysed by genomewide SNP analysis. Rodney J. Scott

How many disease-causing variants in a normal person? Matthew Hurles

Genetics and Genetic Testing for Autism:

No mutations were identified.

Human Genetics 542 Winter 2017 Syllabus

Whole-Genome SNP Array Analysis Genomic Complexity and Clinical Relevance in Prenatal, Postnatal, and Oncology Testing

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Medical Genetics in Undergraduate Medicine

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology

Systematizing in vivo modeling of pediatric disorders

Case Report Severe Psychomotor Delay in a Severe Presentation of Cat-Eye Syndrome

Lab Activity 36. Principles of Heredity. Portland Community College BI 233

AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

The University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Genetics

Microarray analysis deemed best genetic test for autism

PATIENT CONSENT FORM Preimplantation Genetic Screening (PGS) 24 Chromosome Aneuploidy and Translocation Screening with acgh

increment in the genome to calculate the statistic of read count. Three billions according to the reference

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B

The Patient Perspective: diagnostic Exome Sequencing

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Annex III. Amendments to relevant sections of the summary of product characteristics and package leaflets

Transcription:

Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory http://www.nbt.nhs.uk/genetics

Microarray CGH in Prenatal Diagnosis 2012 to 2014 Strict criteria to aid in the reporting decision making process with an expert review panel to offer advice Variants of unknown significance detected in 1-2% General consensus that findings of uncertain significance should not be reported in a prenatal setting

Bristol Prenatal Diagnosis Initial pilot project microarray CGH offered to hospitals At the same time limiting testing for pregnancies referred for Downs risk only, molecular testing and other opportunist samples to an aneuploidy test by QFPCR only Rolled out the use of microarrays for abnormal scan referals to all centres in the South West. copy number variant identified no strong evidence for pathogenicity No not report weak evidence for pathogenicity or evidence of variable penetrance or expressivity clear evidence for pathogenicity Report Contact clinical genetics for advice prior to writing the report

Scan findings VSD, PA>AO 111kb deletion of 10q23.1 - GRID1 Within the much larger 10q22q23 microdeletion syndrome phenotype that includes developmental delay, macrocephaly, cerebellar anomalies, dysmorphism and cardiac defects. Van Bon et al (2011) proposed that GRID1 and BMPR1A may be candidate genes for the cardiac involvement in this syndrome. GRID1 has also been implicated being causative for Schizophrenia in several association studies. Our deletion was intronic and paternally inherited therefore may be unrelated to the scan findings - clinical genetics recommended reporting to the referring obstetrician

Scan finding - hypoplastic left heart A 69kb deletion of 2p16.3 within an intron of NRXN1 NRXN1 deletions -neurosusceptabilty loci with incomplete penetrance no compelling evidence that intronic deletions are causative of a phenotype and so this was not reported A 19kb duplication of Xp22.2 - MID1 non-coding region (5 upstream sequence) mutations cause X linked Opitz GGGB syndrome characterized by hypertelorism, hypospadias, cleft lip/palate, laryngotracheoesophageal abnormalities, imperforate anus, developmental delay, and cardiac defects The foetus was female and the duplication was maternally inherited Consideration of the high burden of a child with Opitz GGGB syndrome and heart defects are associated with this syndrome clinicial genetics recommended reporting This finding was not clearly pathogenic, it may have been related to the abnormalities in the foetus Differences in activation status of the X chromosome between the foetus and the mother could give rise to a different clinical presentation

Scan finding - short femurs 300kb duplication of 10q23.2 which included the genes BMPR1A and GLUD1 BMPR1A - Point mutations, deletions and some duplications of this gene have been reported in association with Juvenile Polyposis syndrome (OMIM#174900).which presents with multiple gastrointestinal polyps and an increased risk of colon cancer GLUD1 - Mutations of have been reported in association with Hyperinsulinism/Hyperammonia syndrome (OMIM#606762) which is an AD disorder whereby episodes of hypoglycemia lead to seizures and mental retardation. Neither of these findings were thought to be related to the scan findings and the duplication was shown to be maternally inherited, but clinical genetics agreed that the duplication was reported

Flexed lower limbs and soft markers Previous CVS raised Downs risk (NT 2.7mm) 484kb deletion of the TAR region at 1q21.1 This deletion when identified in trans with a hypomorphic variant in the RBM8A gene gives rise to TAR syndrome Bilateral radial aplasia and platelet deficiency causing thrombocytopaenia lower limb abnormalities are also sometimes seen. no hypomorphic variant of RBM8A unlikely that this foetus was affected by TAR syndrome There is limited evidence that deletion of this region in individuals without hemizygosity for the hypomorphic variant of RBM8A or features of TAR syndrome may contribute to a variable, abnormal phenotype which may include neurodevelopmental defects This finding was reported

Have concerns about reporting changed? The landscape of prenatal diagnosis has changed certainly locally and probably nationally since that multidisciplinary meeting in February 2014. Prenatal diagnosis has changed from a genome wide analysis by chromosome analysis on a wide range of pregnancies where the indication for testing has been a high Downs risk - the majority no abnormal findings on scan These pregnancies are now only offered a rapid aneuploidy test Followed by karyotype if QFPCR is abnormal Pregnancies with a family history of chromosome abnormality or parental balanced rearrangement

Maybe the history explains the initial concern about reporting findings on microarray of uncertain significance Pregnancies under ongoing microarray analysis are already in a situation of unknown significance there is uncertainty regarding the prognosis especially in the first trimester when scan findings may be limited. Abnormal ultra sound scan may resolve during the pregnancy Good Prognosis uncertainty decision to terminate the pregnancy regardless of the results of genetic testing Termination Additional information useful

Perhaps it can be argued that giving additional information even if it does not lead to a definite prognosis may be helpful in allowing couples to make very difficult decisions regarding their pregnancies. Whilst working in a multidisciplinary way our experience raises the issues of who to talk to and when If there is not national consistency then may we should revisit a national expert review panel The principles developed for array CGH should support the use of other genomic technologies in pregnancy as they are developed e.g. Exomes http://www.nbt.nhs.uk/genetics

Acknowledgements Laboratory staff at BGL Julie-Ann Moore Adele Reynolds Emily Jones Emma Smith Eileen Roberts Catherine Delmege Technical staff Clinical Genetics Consultants Exeter and Bristol Obstetricians Antenatal and Foetal Medicine Units in South West http://www.nbt.nhs.uk/genetics